These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20959470)

  • 1. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo.
    Winer I; Wang S; Lee YE; Fan W; Gong Y; Burgos-Ojeda D; Spahlinger G; Kopelman R; Buckanovich RJ
    Cancer Res; 2010 Nov; 70(21):8674-83. PubMed ID: 20959470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
    Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
    Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
    Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
    Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
    Lu C; Kamat AA; Lin YG; Merritt WM; Landen CN; Kim TJ; Spannuth W; Arumugam T; Han LY; Jennings NB; Logsdon C; Jaffe RB; Coleman RL; Sood AK
    Clin Cancer Res; 2007 Jul; 13(14):4209-17. PubMed ID: 17634550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel model for evaluating therapies targeting human tumor vasculature and human cancer stem-like cells.
    Burgos-Ojeda D; McLean K; Bai S; Pulaski H; Gong Y; Silva I; Skorecki K; Tzukerman M; Buckanovich RJ
    Cancer Res; 2013 Jun; 73(12):3555-65. PubMed ID: 23576551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles for the treatment of intraperitoneal ovarian cancer xenografts.
    Pu C; Chang S; Sun J; Zhu S; Liu H; Zhu Y; Wang Z; Xu RX
    Mol Pharm; 2014 Jan; 11(1):49-58. PubMed ID: 24237050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
    Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
    Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
    Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
    Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF antibody plus cisplatin reduces angiogenesis and tumor growth in a xenograft model of ovarian cancer.
    Ghosh S; Maity P
    J Environ Pathol Toxicol Oncol; 2010; 29(1):17-30. PubMed ID: 20528744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
    Mu J; Abe Y; Tsutsui T; Yamamoto N; Tai XG; Niwa O; Tsujimura T; Sato B; Terano H; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1996 Sep; 87(9):963-71. PubMed ID: 8878460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
    Li D; Williams JI; Pietras RJ
    Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.
    Campbell NE; Greenaway J; Henkin J; Moorehead RA; Petrik J
    Neoplasia; 2010 Mar; 12(3):275-83. PubMed ID: 20234821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer.
    Wang Y; Tong L; Wang J; Luo J; Tang J; Zhong L; Xiao Q; Niu W; Li J; Zhu J; Chen H; Li X; Wang Y
    Acta Biomater; 2019 Aug; 94():495-504. PubMed ID: 31252171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
    Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
    Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
    Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
    Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
    Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
    Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.
    Cocco E; Deng Y; Shapiro EM; Bortolomai I; Lopez S; Lin K; Bellone S; Cui J; Menderes G; Black JD; Schwab CL; Bonazzoli E; Yang F; Predolini F; Zammataro L; Altwerger G; de Haydu C; Clark M; Alvarenga J; Ratner E; Azodi M; Silasi DA; Schwartz PE; Litkouhi B; Saltzman WM; Santin AD
    Mol Cancer Ther; 2017 Feb; 16(2):323-333. PubMed ID: 27956521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.
    Hong B; Chapa V; Saini U; Modgil P; Cohn DE; He G; Siddik ZH; Sood AK; Yan Y; Selvendiran K; Pei G; Zhao Z; Yoo JY; Kaur B
    Clin Cancer Res; 2021 Jan; 27(2):542-553. PubMed ID: 33087329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.